BENDAMUSTINE PLUS RITUXIMAB IN 65 YEAR AND ABOVE UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS

被引：0
|
作者：
De La Fuente, A. [1 ]
Beneit, P. [2 ]
Gutierrez, A. [3 ]
Callejas, M. [4 ]
Garcia Marco, J. A. [5 ]
Garcia Malo, M. D. [6 ]
de la Serna, J. [7 ]
Gonzalez Gascon y Marin, I. [8 ]
Garcia Sanchis, L. [9 ]
Ballesteros, M. [10 ]
Jarque, I. [11 ]
Ochoa Grullon, J. [12 ]
Iglesias, R.
Estevez, M. [1 ]
de Ona, R. [1 ]
Prieto, E. [13 ]
Diaz-Lopez, A. [14 ]
Baltasar, P. [15 ]
机构：
[1] MD Anderson CC Madrid Spain, Hematol, Madrid, Spain
[2] H San Juan, Hematol, Alicante, Spain
[3] HU Son Espases, Hematol, Palma De Mallorca, Spain
[4] HU Principe Asturias, Hematol, Alcala De Henares, Spain
[5] HU Puerta Hierro Majadahonda, Hematol, Madrid, Spain
[6] HGU Morales Meseguer, Hematol, Murcia, Spain
[7] HU 12 Octubre, Hematol, Madrid, Spain
[8] H Infanta Leonor, Hematol, Madrid, Spain
[9] H Gen Castellon, Hematol, Castellon de La Plana, Spain
[10] GU Gregorio Maranon, Hematol, Madrid, Spain
[11] HU La Fe, Hematol, Valencia, Spain
[12] H Clin San Carlos, Inmunol, Madrid, Spain
[13] Hosp Fdn Jimenez Diaz, Hematol, Madrid, Spain
[14] Fdn MD Anderson, Traslat Med, Madrid, Spain
[15] HU La Paz, Hematol, Madrid, Spain
来源：
HAEMATOLOGICA | 2016年 / 101卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
E1082
引用
收藏
页码：445 / 445
页数：1
相关论文
共 50 条
  • [31] Cost-effectiveness of BTK inhibitors vs bendamustine and rituximab in chronic lymphocytic leukemia patients
    Nie, Jing
    Wu, Huina
    Wu, Qian
    Liu, Qi
    Liu, Lihui
    Wu, Jiyong
    FUTURE ONCOLOGY, 2023, 19 (38) : 2525 - 2536
  • [32] Bendamustine in Chronic Lymphocytic Leukemia
    不详
    CLINICAL LYMPHOMA & MYELOMA, 2009, 9 (03): : 203 - 205
  • [33] BENDAMUSTINE AND RITUXIMAB AS FIRST OR SECOND LINE THERAPY IN ELDERLY PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)
    Gozzetti, A.
    Ciolli, S.
    Candi, V.
    Breschi, C.
    Fabbri, A.
    Schiattone, L.
    Cencini, E.
    Papini, G.
    Raspadori, D.
    Defina, M.
    Aprile, L.
    Bosi, A.
    Bocchia, M.
    HAEMATOLOGICA, 2014, 99 : 592 - 592
  • [34] RESULTS OF A PHASE II MULTICENTER STUDY OF OBINUTUZUMAB PLUS BENDAMUSTINE IN PTS WITH PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA
    Danilov, A.
    Yimer, H.
    Boxer, M.
    Di Bella, N.
    Babu, S.
    Li, J.
    Mun, Y.
    Skettino, S.
    Sharman, J.
    HAEMATOLOGICA, 2017, 102 : 71 - 71
  • [35] Final 5-year findings from the phase 3 HELIOS study of ibrutinib plus bendamustine and rituximab in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma
    Fraser, Graeme A. M.
    Chanan-Khan, Asher
    Demirkan, Fatih
    Santucci Silva, Rodrigo
    Grosicki, Sebastian
    Janssens, Ann
    Mayer, Jiri
    Bartlett, Nancy L.
    Dilhuydy, Marie-Sarah
    Loscertales, Javier
    Avigdor, Abraham
    Rule, Simon
    Samoilova, Olga
    Pavlovsky, Miguel A.
    Goy, Andre
    Mato, Anthony
    Hallek, Michael
    Salman, Mariya
    Tamegnon, Monelle
    Sun, Steven
    Connor, Anne
    Nottage, Kerri
    Schuier, Natasha
    Balasubramanian, Sriram
    Howes, Angela
    Cramer, Paula
    LEUKEMIA & LYMPHOMA, 2020, 61 (13) : 3188 - 3197
  • [36] Bendamustine and Rituximab in combination with Lenalidomide in patients with relapsed or refractory and in patients with previously untreated chronic lymphocytic leukemia: A multicenter phase I/II safety and efficacy trial of the German Chronic Lymphocytic Leukemia Study Group (GCLLSG)
    Pflug, N.
    Maurer, C.
    Bahlo, J.
    Kluth, S.
    Rhein, C.
    Cramer, P.
    Gross-Ophoff, C.
    Langerbeins, P.
    Fink, A. -M.
    Eichhorst, B.
    Kreuzer, K. -A.
    Tausch, E.
    Stilgenbauer, S.
    Boettcher, S.
    Doehner, H.
    Kneba, M.
    Hallek, M.
    Wendtner, C. -M.
    Bergmann, M.
    Fischer, K.
    Oncology Research and Treatment, 2015, 38 : 92 - 92
  • [37] Rituximab plus GM-CSF for patients with chronic lymphocytic leukemia.
    Ferrajoli, A
    O'Brien, SM
    Faderl, SH
    Wierda, WG
    Ravandi-Kashani, F
    O'Neal, B
    Schlette, E
    Albitar, M
    Kantarjian, HM
    Keating, MJ
    BLOOD, 2005, 106 (11) : 214A - 214A
  • [38] Bendamustine Combined With Rituximab in Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia: A Multicenter Phase II Trial of the German Chronic Lymphocytic Leukemia Study Group
    Fischer, Kirsten
    Cramer, Paula
    Busch, Raymonde
    Stilgenbauer, Stephan
    Bahlo, Jasmin
    Schweighofer, Carmen D.
    Boettcher, Sebastian
    Staib, Peter
    Kiehl, Michael
    Eckart, Michael J.
    Kranz, Gabriele
    Goede, Valentin
    Elter, Thomas
    Buehler, Andreas
    Winkler, Dirk
    Kneba, Michael
    Doehner, Hartmut
    Eichhorst, Barbara F.
    Hallek, Michael
    Wendtner, Clemens-Martin
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (26) : 3559 - 3566
  • [39] BRUIN CLL-313: A Phase 3 Open-Label, Randomized Study of Pirtobrutinib Versus Bendamustine Plus Rituximab in Untreated Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (Trial in Progress)
    Jurczak, Wojciech
    Dartigeas, Caroline
    Coscia, Marta
    Ganly, Peter S.
    Al-Jazayrly, Ghassan
    Wang, Chunxiao
    Bao, Katherine
    Leow, Ching Ching
    Shahda, Safi
    Zinzani, Pier Luigi
    BLOOD, 2021, 138 : 3732 - +
  • [40] Final 5-Year Updated Results From a Phase 3 Study (HELIOS) of Ibrutinib Plus Bendamustine and Rituximab in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2019, 17 (11) : 17 - 19
12345